Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
December 17 2008 - 8:00AM
PR Newswire (US)
NEW YORK, Dec. 17 /PRNewswire-FirstCall/ -- Delcath Systems, Inc.
(NASDAQ: DCTH) today announced the appointment of Pamela R. Contag,
Ph.D., to Delcath's Board of Directors. Dr. Contag is a proven
corporate executive with extensive experience working with
international and domestic investors. (LOGO:
http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO ) Dr.
Contag founded Cobalt Technologies, Inc. in 2006 and served as CEO.
Prior to starting Cobalt, she founded Xenogen Corporation, a
biotechnology company specializing in technology and services for
preclinical drug development and testing. She served as President
and Director of Xenogen from 1995 to 2006. Xenogen, which became a
public company in 2004, was acquired by Caliper Life Sciences in
2006. Xenogen Corporation was listed as one of the "Top 25 Young
Businesses" by Fortune Small Business and twice received the
"R&D 100 Award." Dr. Contag was also recognized as one of the
"Top 25 Women in Small Business" by Fortune magazine. Dr. Contag
received her Ph.D. in Microbiology from the University of Minnesota
Medical School and completed her postdoctoral training at Stanford
University School of Medicine. Dr. Contag is a consulting Professor
at the Stanford School of Medicine and is widely published in the
field of non-invasive molecular and cellular imaging. Richard L.
Taney, President and Chief Executive Officer of Delcath, welcomed
Dr. Contag to the Board, stating, "Delcath continues to add
strategic insight and expertise to our Board of Directors as we
focus on the completion of our trial and approval of the Delcath
PHP System. Dr. Contag's biotech, pharmaceutical and testing
experience will be particularly relevant as we prepare for meetings
with the FDA regarding regulatory approvals and ultimately,
commercialization. Her extensive industry relationships will
provide opportunities to expand the recognition and value of the
Delcath technology. The recent clinical milestones, and addition of
key management and Board members over the past six months, have
positioned our Company well, as enrollment continues to accelerate
and we move towards completion of our Phase III trial." About
Delcath Systems, Inc. Delcath Systems, Inc. is a medical technology
company specializing in cancer treatment. The Company is testing a
proprietary, patented drug delivery system for the treatment of
liver cancers. Delcath's novel drug delivery platform is testing
the delivery of ultra-high doses of anti-cancer drugs to the liver
while preventing these high doses of drug from entering the
patient's bloodstream. The Company is currently enrolling patients
in Phase III and Phase II clinical studies for the treatment of
liver cancers using high doses of melphalan. The Company's
intellectual property portfolio consists of twenty-eight patents on
a worldwide basis including the U.S., Europe, Asia and Canada. For
more information, please visit the Company's website at
http://www.delcath.com/ The Private Securities Litigation Reform
Act of 1995 provides a safe harbor for forward-looking statements
made by the Company or on its behalf. This news release contains
forward-looking statements, which are subject to certain risks and
uncertainties that can cause actual results to differ materially
from those described. Factors that may cause such differences
include, but are not limited to, uncertainties relating to our
ability to successfully complete Phase III clinical trials and
secure regulatory approval of our current or future drug-delivery
system and uncertainties regarding our ability to obtain financial
and other resources for any research, development and
commercialization activities. These factors, and others, are
discussed from time to time in our filings with the Securities and
Exchange Commission. You should not place undue reliance on these
forward-looking statements, which speak only as of the date they
are made. We undertake no obligation to publicly update or revise
these forward-looking statements to reflect events or circumstances
after the date they are made.
http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGODATASOURCE:
Delcath Systems, Inc. CONTACT: Richard Taney, +1-212-489-2100, ,
for Delcath Systems, Inc.; Public Relations Contact: Robin Wagge,
+1-212-843-8006, , of Rubenstein Associates, Inc. for Delcath
Systems Web Site: http://www.delcath.com/
Copyright